Moderna (MRNA)
(Delayed Data from NSDQ)
$65.69 USD
-2.33 (-3.43%)
Updated Sep 20, 2024 04:00 PM ET
Pre-Market: $65.90 +0.21 (0.32%) 8:50 AM ET
4-Sell of 5 4
F Value C Growth F Momentum F VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$65.69 USD
-2.33 (-3.43%)
Updated Sep 20, 2024 04:00 PM ET
Pre-Market: $65.90 +0.21 (0.32%) 8:50 AM ET
4-Sell of 5 4
F Value C Growth F Momentum F VGM
Zacks News
Biotech Stock Roundup: MRNA Submits Vaccine Data, BMRN Down on Clinical Hold & More
by Zacks Equity Research
Regulatory and pipeline updates from Moderna (MRNA) and BioMarin (BMRN), among others, have been in focus in the biotech industry over the past week.
Moderna (MRNA) Inks Deal to Develop Ultra-Rare Disease Therapy
by Zacks Equity Research
Moderna (MRNA) inks a collaboration deal with the Institute for Life Changing Medicines to develop a free of charge mRNA-based therapy to treat Crigler-Najjar Syndrome type 1, an ultra-rare disease.
Illumina (ILMN), Merck Ink Cancer Companion Diagnostics Deal
by Zacks Equity Research
Illumina (ILMN) collaborated with Merck to develop and commercialize companion diagnostics to identify ovarian cancer patients with positive HRD status for treatment with LYNPARZA.
AstraZeneca's (AZN) Ultomiris Gets EU Nod for Rare Disease in Kids
by Zacks Equity Research
AstraZeneca's (AZN) Ultomiris receives expanded approval in the EU to treat children and adolescents with PNH, a rare disease.
Moderna (MRNA) Seeks Authorization for Booster Dose in Europe
by Zacks Equity Research
Moderna (MRNA) is developing a booster dose of its COVID-19 vaccine, mRNA-1273, for enhancing protection against infection in individuals.
Techne (TECH) Soars to 52-Week High, Time to Cash Out?
by Zacks Equity Research
Techne (TECH) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
3 Large Biotech Stocks Worth Adding to Your Portfolio
by Zacks Equity Research
REGN, MRNA & VRTX are the three biotech companies that are likely to outperform the sector on the back of strong fundamentals.
Moderna (MRNA) Gives First COVID Jab Booster Data to the FDA
by Zacks Equity Research
Moderna's (MRNA) booster dose of COVID-19 vaccine elicits antibody levels that were much higher than that seen after the two-dose primary schedule.
Moderna (MRNA) Japan Jabs Resume Amid Safety Risk Per Reports
by Zacks Equity Research
Japan allows use of uncontaminated vials from the same lots of Moderna's (MRNA) COVID-19 vaccine that had some contaminated vials, which led to the temporary halt of vaccination in some parts of the country.
Sorrento's (SRNE) COVID Vaccine Effective in Pre-Clinical Study
by Zacks Equity Research
Sorrento (SRNE) announces data from pre-clinical study for its investigational mRNA COVID vaccine. The company also in-licensed rights to highly potent main protease inhibitors against COVID variants.
Pfizer (PFE) Inks Deal With Eurofarma to Make COVID-19 Vaccine
by Zacks Equity Research
Pfizer (PFE) and partner BioNTech ink a collaboration deal with Brazil's Eurofarma for manufacturing and supplying their COVID-19 vaccine, Comirnaty, in Latin America.
5 Bigwigs to Buy on Double-Digit Returns in the Past Month
by Nalak Das
We have narrowed down our search to five U.S. corporate bigwigs that have provided more than 10% returns in the past month. These are: MRNA, REGN, AIG, CARR and NVDA.
Biotech Stock Roundup: REGN, MRNA Offer COVID-19 Updates, TBPH Down on Study Update
by Zacks Equity Research
Regulatory and pipeline updates from Regeneron (REGN) and Moderna (MRNA), among others have been in focus in the biotech industry over the past week.
Has Moderna (MRNA) Outpaced Other Medical Stocks This Year?
by Zacks Equity Research
Is (MRNA) Outperforming Other Medical Stocks This Year?
Pfizer (PFE), BioNTech Seek Full Approval for COVID Jab Booster
by Zacks Equity Research
The booster dose of Pfizer (PFE)/BioNTech's (BNTX) mRNA-based COVID-19 vaccine, Comirnaty dose induced significant SARS-CoV-2 neutralizing antibody titers in phase III study.
Tap the Red Hot Biotech Sector With These 2 Leveraged ETFs
by Sweta Killa
Investors could easily tap the bullish trend by considering a near-term long on the biotech sector.
J&J (JNJ) Reports Positive Interim Data on COVID Booster Jab
by Zacks Equity Research
The booster dose of J&J's (JNJ) single-shot COVID-19 vaccine achieves rapid and robust increase in spike-binding antibodies in previously vaccinated people with the initial dose.
Moderna (MRNA) Seeks Full FDA Approval for COVID-19 Vaccine
by Zacks Equity Research
Moderna (MRNA) completes rolling submission of BLA to the FDA seeking full approval of its COVID-19 vaccine candidate, mRNA-1273, in the United States.
The Zacks Analyst Blog Highlights: Apple, Regeneron Pharmaceuticals, TJX Companies, Moderna and NVIDIA
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Apple, Regeneron Pharmaceuticals, TJX Companies, Moderna and NVIDIA
Nasdaq Tops 15K for First Time: 5 Best Stocks in the ETF
by Sweta Killa
The tech-heavy Nasdaq Composite Index topped 15,000 for the first time ever driven by continued strength in tech stocks.
Vertex (VRTX) Inks New Deal for CRISPR Gene-Editing Rights
by Zacks Equity Research
Vertex (VRTX) collaboration with Arbor will support discovery & development of new treatment options for serious diseases using the latter's CRISPR technology.
The Zacks Analyst Blog Highlights: Pfizer, BioNTech, Moderna, Johnson & Johnson and Novavax
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Pfizer, BioNTech, Moderna, Johnson & Johnson and Novavax
6 Must-Buy Corporate Giants As Major Indexes Hit Record High
by Nalak Das
We have narrowed down our search to six stocks that are members of any of the three major indexes. These are: MRNA, NVDA, TJX, AAPL, DE and REGN.
Nasdaq Crosses 15K for 1st Time Ever; JWN, URBN Beat
by Mark Vickery
On the way to its fourth-straight up day in the market, the tech-heavy Nasdaq wound up surpassing 15K for its first time ever.
3 COVID Vaccine Makers to Watch on Pfizer Jab Full FDA Approval
by Zacks Equity Research
Stocks of coronavirus vaccine makers BNTX and MRNA fly high following complete approval of Pfizer's COVID-19 vaccine. The momentum is likely to continue for these stocks. JNJ is another strong contender in this field.